<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613946</url>
  </required_header>
  <id_info>
    <org_study_id>22-006006</org_study_id>
    <nct_id>NCT05613946</nct_id>
  </id_info>
  <brief_title>Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema</brief_title>
  <acronym>CASTLE</acronym>
  <official_title>Contrast-enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema (CASTLE) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine the preferred microbubble agent (Lumason®,&#xD;
      Optison®, and Definity®) for lymphatic channel visualization by ultrasound. This research&#xD;
      will also evaluate the utility of preoperative high-frequency B-mode ultrasound with&#xD;
      contrast-enhanced ultrasound for presurgical planning, and ultrasound shear wave elastography&#xD;
      for assessing treatment response at 6-month follow up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 - Evaluate the uptake of microbubble agent (Lumason®, Optison®, and Definity®) for&#xD;
      lymphatic visualization by ultrasound.&#xD;
&#xD;
      Part 2 - Combine preoperative high-frequency B-mode ultrasound with contrast-enhanced&#xD;
      ultrasound to identify patent lymphatic channels for lymphaticovenous anastomosis presurgical&#xD;
      planning. Evaluate the utility of ultrasound shear wave elastography for assessing treatment&#xD;
      response at 6-month follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2022</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lymphatic vessel visualization</measure>
    <time_frame>5 minutes after injection</time_frame>
    <description>The time from injection to lymphatic visualization, the duration of contrast visualization, and the longest length of lymphatic channel visualized for each injection site will be determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-frequency ultrasound and shear-wave elastography</measure>
    <time_frame>1.5 hours for intraoperative CEUS and out-patient SWE both at baseline and 6-month follow-up</time_frame>
    <description>Identify any patent lymphatic channels on CEUS or high-frequency ultrasound that were not detected by the reference standard ICG lymphography. We will additionally measure dermal thickness on B-mode ultrasound and perform SWE at levels comparable to the lymphedema grading metrics routinely collected at surgical visits.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Lymphedema Arm</condition>
  <arm_group>
    <arm_group_label>Microbubble contrast agent Lumason</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>While subjects are undergoing standard of operation for arm with lymphedema, the healthy arm will receive intradermal injection of microbubbles and imaged immediately by ultrasound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microbubble contrast agent Optison</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>While subjects are undergoing standard of operation for arm with lymphedema, the healthy arm will receive intradermal injection of microbubbles and imaged immediately by ultrasound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microbubble contrast agent Definity</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>While subjects are undergoing standard of operation for arm with lymphedema, the healthy arm will receive intradermal injection of microbubbles and imaged immediately by ultrasound.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumason</intervention_name>
    <description>Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity</description>
    <arm_group_label>Microbubble contrast agent Lumason</arm_group_label>
    <other_name>sulfur hexafluoride lipid-type A microspheres</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optison</intervention_name>
    <description>Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity</description>
    <arm_group_label>Microbubble contrast agent Optison</arm_group_label>
    <other_name>perflutren protein-type A microspheres</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Definity</intervention_name>
    <description>Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity</description>
    <arm_group_label>Microbubble contrast agent Definity</arm_group_label>
    <other_name>perflutren lipid microsphere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unilateral lymphedema in the upper extremity (ISL stage 2 or 3) secondary to breast&#xD;
             cancer or breast cancer treatment.&#xD;
&#xD;
          -  Patient qualifies for LVA surgery as determined by the plastic surgeons performing the&#xD;
             surgery (Dr. Bill Tran or Dr. Vahe Fahradyan), and the patient consents to surgery.&#xD;
&#xD;
          -  Patient must be able to come to the 6-month clinical follow-up appointment (Part 2&#xD;
             only).&#xD;
&#xD;
          -  Patients must be able to understand the study procedures and comply with them for the&#xD;
             entire length of the study.&#xD;
&#xD;
          -  No contraception is necessary or required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to microbubble contrast agent, perflutren, blood&#xD;
             products, albumin, polyethylene glycol (PEG), or egg.31.&#xD;
&#xD;
          -  Known or suspected cardiac shunts.&#xD;
&#xD;
          -  Prior lymphedema surgery in the upper extremity.&#xD;
&#xD;
          -  Tattoo or scar on either upper extremity.&#xD;
&#xD;
          -  Current drug or alcohol use or dependence that, in the opinion of the investigator,&#xD;
             would interfere with adherence to study requirements.&#xD;
&#xD;
          -  Inability or unwillingness of individual or legal guardian/representative to give&#xD;
             written informed consent..&#xD;
&#xD;
          -  Current or past participation within a specified timeframe in another clinical trial,&#xD;
             as warranted by the administration of this intervention.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karlyn Pierson, RN, CCRP</last_name>
      <phone>507-538-8706</phone>
      <email>pierson.karlyn@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>January 13, 2023</last_update_submitted>
  <last_update_submitted_qc>January 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Christine U. Lee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lymphaticovenous anastomosis surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

